Ethics of Offshoring Novo Nordisk

decisive issued of the appropriateness of conducting clinical trials in rising countries has arisen any(prenominal)where years. Being a tip company in biopharmaceutical industry, Novo Nordisk faces the critiques of whether it is justice to completeshoring their clinical trials in developing economies. With the consistency of honourable principles brought up by Novo Nordisk, the company would be able to move their trials into emerge economies with the come outflank disport for stakeholders.I get out overly propose ideas to Mr, Dejgaard for possible approach to media as well as the practices that Novo Nordisk could have changed over time at the end. Conducting Clinical Trials in Emerging Economies With Utilitarian approach, every political party has various perspectives in the outcome of an performance. In this case, we have sh beholders, employees, customers, supply chain, regime and local communities, with secondary stakeholders of media, special interest groups an d NGOs.For customers, government and local communities, they emphasize more on the proof of efficacy and safety of aesculapian products. While shareholders, employees, supply chain lot more of the usefulnessability as a on the whole in general. As a result, Novo Nordisk give be stop off maximizing its profits go place their honorable justice for conducting clinical trials in acclivitous countries. Economic AspectAs the Nobel prize winner, Milton Friedman pointed out that making profit go forth be the first antecedence for business to fulfill affable responsibility, Novo Nordisk has every right to maximize its crush interest for its stakeholders include shareholders, employees, customers, suppliers, governments and local communities. From financial proceeding stand point, conducting clinical trials in emerging economies benefits Novo Nordisk from saving costs, accessing to larger demographic participant, obeying less(prenominal) strict rules applied, and establishing e fficacy in different environmental onditions. good Aspect On the otherwise hand, firms should consider the corporate social responsibility brought by the society. Firms definitely get hold of to incorporate their elevatedest moral standards to build cuss and reputation for themselves in order to interrupt off in long run. Novo Nordisk ceaselessly celebrates the regulation from capital of Finland Declaration with other international honourable guidelines. They made plastered that the interest and well- universe of the trial matter should always transcend over the interest of science, society and commerce. Decision PrinciplesEven though I think conducting clinical trials in emerging economies is beneficial to the firm, Novo Nordisk should still follow below guidelines for this major decision to nurse its own reputation and serve the best interest for every stakeholder Execute clinical trials when the internal organization is well schematic and external environment is p roper correct in emerging countries. Conduct placebo clinical trials when they are scientific ally and honourablely justified. visit the human rights of the participants in emerging countries associated with the sure risksResponses to The Media I understand that Mr. Dejaard holds a high ethical stands, and is not interested in misleading the public or ethical dissembling in the resolution. It is overly all important(predicate) to clear up the actions Novo Nordisk has taken for the historic years and give public a clear picture of how the firm is operating. If a journalist is inviting for an interview, Mr. Dejaard should present himself into the public and response to the inquiry people have, otherwise, absence will only show irresponsible kitchen range that he might try to fly from the issue. Medical Ethics I will suggest Mr.Dejaard to pull out historical data indicating that the random checks investigated from Food and drug Administration (FDA), the American and Europ ean political science have never identified ethical problems in clinical trials in emerging economies. Second, assert the ethic codes from their company will help the publics to receive the image of Novo Nordisk has complied with the Helsinki Declaration of the World Medical Association. Ethical Business Media might inquiry the law of conducting placebo experiment in emerging countries by Novo Nordisk based on the industry trends in recent time.Mr. Dejaard could response to them that Novo Nordisk usually mystify away from placebo trials, and only use in phase 1 trials which only legal volunteers participated. Also, Novo Nordisk framed new business moral philosophy policy in 2005 with generally authentic high standards while training managers and employees attendance workshops and offering e-learning policy. To better respond to the media, Mr. Dejaard could also indicate that Novo Nordisk will try to put through some new action stick out that could benefit stakeholders as a w hole in order to minimize ethical conflicts.I suggest the following action plan for Novo Nordisk to benefit them in long run. Action Plan Enhance Auditing constitution To build trust for the stakeholder for Novo Nordisk, I look at the firm should develop a more solid auditing system. Instead auditing 10% of all trials, Novo Nordisk should increase the rate up to 50% or more. From a public view, 10% of investigating in all trials is not sufficient enough to prove that the trials are ethical conducted. With the increasing number of trials being audited and investigated, the quality of the clinical trials could be better controlled.Build up Placebo Experiment ensample In the Clinical Trials Novo Nordisks Position, it pointed out that placebo will only be used as comparator when scientifically and ethical justified. It is sort of unclear for public to know what would be an appropriate placebo experiment for Novo Nordisk to conduct while proven therapy is available. It is important t o insiders to identify whether or not conducting placebo experiment under certain circumstances will have any additional risk and irreversible harm.